Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer or Solid Tumors With Bone Metastases

NCT06069570 is registered in ClinicalTrials.gov with Kiromic BioPharma Inc. as lead sponsor.

NCT NCT06069570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06069570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer or Solid Tumors With Bone Metastases
Lead sponsor
Kiromic BioPharma Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
November 7, 2023
Completion date
October 31, 2026
Enrollment
48 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases from solid tumors, carcinoma, non-small-cell lung cancer